The top documents tagged [openlabel phase]

Rodman renshaw report on onty
Investor Relations Rodman renshaw report on onty

1.194 views

Raccomandazioni di AIOM e SIAPEC-IAP Nicola Normanno ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G. Pascale – NAPOLI SC Biologia Cellulare
Documents Raccomandazioni di AIOM e SIAPEC-IAP Nicola Normanno ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G. Pascale – NAPOLI SC Biologia Cellulare

219 views

The Lancet - Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label
Documents The Lancet - Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label

119 views

Mmc1 2 The Lancet - Supplementary appendix 10/15/2014
Data & Analytics Mmc1 2 The Lancet - Supplementary appendix 10/15/2014

104 views

ppt
Documents ppt

373 views

Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th International AIDS Conference
Health & Medicine Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th International AIDS Conference

4.813 views

Cco clin onc_june _2012_lymphoma_slides
Documents Cco clin onc_june _2012_lymphoma_slides

42 views

Clinicaloptions.com/hepatitis Highlights of AASLD 2012 Highlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American
Documents Clinicaloptions.com/hepatitis Highlights of AASLD 2012 Highlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American

216 views

A Phase III study (EMBRACE*) of eribulin mesylate vs. treatment of physician’s choice in patients with locally recurrent or metastatic breast cancer previously
Documents A Phase III study (EMBRACE*) of eribulin mesylate vs. treatment of physician’s choice in patients with locally recurrent or metastatic breast cancer previously

220 views

IAS 2015, Vancouver Subjects with Renal Impairment Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety
Documents IAS 2015, Vancouver Subjects with Renal Impairment Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety

218 views

IO_DEB TACE IO Journal Club Primer Final.pdf
Documents IO_DEB TACE IO Journal Club Primer Final.pdf

277 views

FDA Analyses of Maraviroc Safety Data Scott Proestel, M.D. Division of Antiviral Products Food and Drug Administration April 24, 2007
Documents FDA Analyses of Maraviroc Safety Data Scott Proestel, M.D. Division of Antiviral Products Food and Drug Administration April 24, 2007

274 views